Drugs / AX-158
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05218434 | Nov 2021 → Nov 2022 | autoimmune disease | Artax Biopharma Inc | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05725057 Comparator | Nov 2023 → Sep 2024 | psoriasis | Artax Biopharma Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2025-05-09 | Artax Biopharma Inc | Results Artax Biopharma presents Phase 2a results for oral Nck modulator AX-158 in late-breaking session at the Society for Investigative Dermatology 2025 Annual Meeting artaxbiopharma.com ↗ |
| 2025-03-07 | Artax Biopharma Inc | Results Artax Biopharma presents new preclinical data on Nck modulators at 2025 AAD Annual Meeting artaxbiopharma.com ↗
Treatment of healthy PBMCs with AX-158 resulted in a dose-dependent reduction in cytokine release across all T helper cell subtypes including IL-17, IL-4 and IL-13. |
| 2025-01-22 | Artax Biopharma Inc | Results Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study artaxbiopharma.com ↗
Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces achievement of clinical validation through its Phase 2a clinical trial in psoriasis with fully proprietary oral agent AX-158. |
| 2024-10-01 | Artax Biopharma Inc | Results Artax Biopharma to present first-in-class Nck modulator mechanism of action and Phase 1 data at the ACR Annual Meeting artaxbiopharma.com ↗
Phase 1 data with AX-158 confirm mechanism and support continued clinical studies |
| 2023-11-09 | Artax Biopharma Inc | Regulatory Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study artaxbiopharma.com ↗
Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of T Cell-mediated diseases, today announces that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted clinical trial authorization (CTA) to evaluate AX-158 in a Phase 2a psoriasis study. |
| 2023-06-01 | Artax Biopharma Inc | Results Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases artaxbiopharma.com ↗
The Phase 1 clinical trial findings demonstrated that AX-158: had no related adverse events in the clinical trial; was well tolerated at all doses, up to the maximum of 50mg QD in the single ascending dose cohorts and up to the maximum of 15mg QD for 10 days in the multiple ascending dose cohorts; |
| 2021-07-13 | Artax Biopharma Inc | Regulatory Artax Biopharma Granted MHRA Clinical Trial Authorization for AX-158 artaxbiopharma.com ↗
Artax Biopharma, Inc., a biotechnology company focused on transforming the treatment of T Cell-mediated diseases, today announced that the United Kingdom’sMedicines and Healthcare Products Regulatory Agency (MHRA) has granted clinical trial authorization to evaluate AX-158 in a Phase 1 clinical trial for the treatment of T Cell- Mediated Diseases. |
All press releases naming this drug 12 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AX-158 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05218434 ↗ |
| Route | Oral | “Oral administrations of AX-158” NCT05218434 ↗ |